An interventional study of oral immunotherapy in Food Allergy, sponsored by Deventer Ziekenhuis. Enrolling by invitation at 4 sites in Netherlands. Open to participants aged 9 Months to 30 Months. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Deventer Ziekenhuis · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Food Hypersensitivity with a site in Netherlands — 2 open to participants now, 4 under way, 2 of them phase 3. Food Hypersensitivity · Netherlands.
Among the 12 studies in Food Hypersensitivity with a site in Netherlands, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 with no phase, and was the 8th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.
Browse Food Hypersensitivity studies →2 of the 12 studies in Food Hypersensitivity with a site in Netherlands are open now. Recruiting first, the newest first:
Martini Hospital Groningen · Sites in Netherlands
Ages 1 mo–18 mo
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 53 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 41 (77%) stop at 75 or younger; 45 take children under 18; 17 take healthy volunteers.
This study: 9 Months to 30 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 500 is above the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 171 across the 11 interventional studies, 3 across the 1 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 7 most frequent:
Deventer Ziekenhuis is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Deventer Ziekenhuis has 1 study filed under Food Hypersensitivity — fewer than ten, so there is no comparison to draw.
1 of the studies in Food Hypersensitivity with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Food Hypersensitivity with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn about oral immunotherapy in food allergic children \< 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Participants will receive oral immunotherapy for 1 year with a maintenance dose of 300 mg allergenic protein and are compared with food allergic infants not receiving oral immunotherapy to compare with natural tolerance development.
Primary objective: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction in children under the age of 30 months with an established food allergy compared to routine care? Secondary objective: What is the effect of early low-dose oral immunotherapy in children under the age of 30 months with an established food allergy on (allergy specific) quality of life of parents and children compared to routine care? Study design: randomized controlled superiority trial Study population: Children between 9 and 30 months old with an IgE-mediated food allergy to peanut, tree nuts, cow's milk and/or hen's egg as proven by an oral food challenge. Intervention: 1-year low-dose oral immunotherapy (daily 300 mg allergenic protein) compared to strict avoidance in the control group.
Main study parameters/endpoints: Long-term tolerance as assessed by an exit oral food challenge at 4 weeks after discontinuation of the oral immunotherapy, combined with uncomplicated consumption of a full dose of the specific food at 6 months after discontinuation of the therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
oral immunotherapy, maintenance phase with daily 300 mg allergenic protein during 1 year
Dietary Supplement: oral immunotherapy
strictly avoidance of the specific allergenic food
oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
Percentage of patients with sustained unresponsiveness to consumption of a specific allergenic food 4 weeks after stopping the 1-year oral immunotherapy (OIT)
Definition of sustained unresponsiveness: a participant who passed an oral food challenge (OFC) to 4.2 gram of the allergenic protein. Definition of the allergenic protein: the allergenic protein which induced an allergic response at an OFC at the start of the study, and was administered to the patient during the OIT (i.e. milk, egg, peanut, hazelnut, cashew or walnut).
Time frame: Timing of the OFC: week 57 (52 weeks of OIT, followed by a 4-week allergenic food-free interval)
Percentage of tolerant participants at week 78
In children achieving sustained unresponsiveness (outcome 1), the allergen is introduced into the diet by parents at a regular base. Six months after discontinuation of the OIT, tolerance to the specific allergenic protein is assessed. Definition of tolerant: Percentage of children with uncomplicated (i.e. without any allergic symptoms) consumption at home of a full dose of the specific allergenic protein (e.g. a glass of milk or a sandwich with peanut butter).
Time frame: week 78 = 6 months after stop of the 1-year oral immunotherapy
Cost-effectiveness ratio at 18 months (week 78).
Incremental cost-effectiveness ratio (ICER) at 18 months (week 78). Costs associated with oral immunotherapy will be measured in Euros. Effectiveness will be considered as percentage of tolerant participants at week 78.
Time frame: 18 months (week 78).
Cost-utility ratio at 18 months (week 78).
Incremental cost-utility ratio (ICUR) will be calculated for both groups using health-related quality of life (HRQoL) scores from the AQoL-6D (assessment of quality of life - 6 dimensions) and converted to utility scores and will be expressed in euros per QALY.
Time frame: 18 months (week 78): at the end of the study period.
Health related quality of life of children, during the 1-year OIT and six months after the therapy (week 78)
Children's quality of life as measured by: \- Food Allergy Quality of Life Questionnaire - parental form (FAQLQ-PF) This questionnaire consists of 14 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no impact of food allergy on quality of life), maximum score is 84 (high impact of food allergy on quality of life)
Time frame: during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)
Occurrence of Adverse Event(s) Related to Oral Immunotherapy up to 65 weeks study participation
(Serious) adverse events related to oral immunotherapy
Time frame: during build-up (up to 3 months) and 1-year oral immunotherapy, total 65 weeks
Levels of allergy-related immune parameters
Levels of allergen specific IgE and IgG4
Time frame: at start of the therapy and after 6 and 12 months maintenance therapy
adherence
Rate of daily providing the oral immunotherapy
Time frame: during 1 year oral immunotherapy
Health related quality of life of parents, during the 1-year OIT and six months after the therapy (week 78)
Parental quality of life as measured by: \- Food Allergy Quality of Life- Parental Burden (FAQL-PB) This questionnaire consists of 17 questions to be answered on a 7-point Likert-scale. Minimum score is 0 points (no parental burden), maximum score is 102 (severe parental burden)
Time frame: during oral immunotherapy (T=0, 26 weeks and 52 weeks), and 6 months after stopping the oral immunotherapy (78 weeks)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data collected for this study will be stored in SPSS and Excel and analyzed in SPSS. Access to trial IPD can be requested after the study is completed by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact wetenschapsbureau@dz.nl
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: 01-07-2025 - 01-07-2026
Access criteria: Researchers wanting to use the data would have to contact the PIs with a research proposal and Statistical Analysis Plan (SAP).
Started Feb 2023 (actual). Primary completion is estimated for Aug 2026, 42 months after the start.
Of 82 non-industry interventional studies with no phase under Food Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 42 months is above that.
Counting every sponsor, half of 86 studies reached it within 30 months; a quarter within 13 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Deventer Ziekenhuis